Ascentage Pharma Group International (AAPG)
$14.85-1.39%Close
SELLBEAR · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $345M
- Beta
- 0.66
- P/E (TTM)
- -6.37
- Short % float
- 0.14%
- Days to cover
- 1.5
- SI change
- -53.4%
- 1W
- -0.60%
- 1M
- -7.19%
- vs SPY 1W
- +0.38%
- vs SPY 1M
- -9.05%
Industry peers
FMP comparable companies · ranked by market cap
- TNGXSELLTango Therapeutics, Inc.$3.9BRECOVERYQ 23$23.81-0.14%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 24$36.11-1.17%
- ZLABSELLZai Lab Limited$2.8BCRISISQ 8$24.99-2.60%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 12$22.35+6.96%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$5.00-0.85%
- ANLSELLAdlai Nortye Ltd.$829MCRISISQ 9$15.62-7.48%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -6$16.73+0.68%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38+3.49%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AAPG?
- LOPJLB’s latest quantitative signal on Ascentage Pharma Group International (AAPG) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is AAPG in?
- Ascentage Pharma Group International (AAPG) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Ascentage Pharma Group International (AAPG) do?
- Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR…